KYMR — Kymera Therapeutics, Inc. stock price, charts and financials

Latest market price

108.58

+1.06+0.99%

Overview Short InterestFilings

KYMRQT75Kymera Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

108.58+0.99%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CRNX+0.08%$84.15 SYRE+0.40%$105.33 NUVL+0.00%$123.96 PCVX+0.38%$58.29 APGE-0.14%$134.65 PTGX+2.83%$150.00 IONS+0.67%$56.94 ALKS+0.47%$49.40

Snapshot

Index	-	P/E	-	EPS (ttm)	-3.58	Insider Own	23.61%	Shs Outstand	82.26M	Perf Week	3.98%

Market Cap	8.84B	Forward P/E	-	EPS next Y	-4.78	Insider Trans	-20.95%	Shs Float	72.95M	Perf Month	-9.65%

Enterprise Value	8.80B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	13.57%	Perf Quarter	27.05%

Income	-251.18M	P/S	84.24	EPS this Y	-3.72%	Inst Trans	-	Short Ratio	12.65	Perf Half Y	41.59%

Sales	104.99M	P/B	6.99	EPS next Y	-28.73%	ROA	-18.21%	Short Interest	9.90M	Perf YTD	38.18%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-21.50%	52W High	131.33 -17.32%	Perf Year	160.02%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-22.14%	52W Low	37.01 193.37%	Perf 3Y	400.09%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-6.03% 2.78%	Gross Margin	-	Volatility	3.66% 4.23%	Perf 5Y	78.66%

Dividend TTM	-	EV/Sales	83.84	EPS Y/Y TTM	-20.13%	Oper. Margin	-333.54%	ATR (14)	4.92	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	9.91	Sales Y/Y TTM	8.51%	Profit Margin	-285.41%	RSI (14)	51.85	Recom	2.15

Dividend Gr. 3/5Y	-	Current Ratio	9.83	EPS Q/Q	13.41%	SMA20	-1.27%	Beta	1.90	Target Price	129.64

Payout	0.00%	Debt/Eq	0.05	Sales Q/Q	54.55%	SMA50	6.99%	Rel Volume	0.58	Prev Close	107.52

Employees	238	LT Debt/Eq	0.04	Earnings	Nov 03	SMA200	29.10%	Avg Volume	793.63K	Price	108.58

IPO Date	Aug 21, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	19.37% 315.71%	Net Debt/EBITDA	0.14	Volume	463,571	Change	0.99%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-06-26	Reiterated	Morgan Stanley	Overweight	$119 → $135
Aug-06-26	Reiterated	Barclays	Overweight	$133 → $139
Aug-05-26	Reiterated	Oppenheimer	Outperform	$120 → $125
Jul-30-26	Reiterated	Deutsche Bank		$120
Jul-28-26	Reiterated	Guggenheim	Buy	$90 → $135
Jul-16-26	Reiterated	Mizuho	Outperform	$120 → $140
Jul-13-26	Downgrade	RBC Capital	Outperform → Sector Perform	$108 → $115
Jun-29-26	Reiterated	Truist Securities	Buy	$116 → $136
Jun-26-26	Reiterated	Canaccord Genuity	Buy	$106 → $129
Jun-08-26	Reiterated	Loop Capital Markets		$97

Latest News

Aug-06-26

Aug-06-2603:56PM

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Paymentszacks.com

10:00AM

Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139Benzinga

Aug-05-26

Aug-05-2603:40PM

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcriptseekingalpha.com

01:06PM

Kymera Therapeutics Q2 Earnings Call Highlightsmarketbeat.com

09:16AM

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimateszacks.com

07:00AM

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Updateglobenewswire.com

Jul-30-26

Jul-30-2611:41AM

This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For ThursdayBenzinga

08:05AM

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More247wallst.com

Jul-28-26

Jul-28-2604:01PM

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026globenewswire.com

Jul-27-26

Jul-27-2604:01PM

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officerglobenewswire.com

08:49AM

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firmprnewswire.com

Jul-26-26

Jul-26-2602:02AM

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up – Here’s Whydefenseworld.net

Jul-24-26

Jul-24-2612:21PM

Is Kymera Therapeutics Poised for a Breakthrough With KT-621?zacks.com

Jul-21-26

Jul-21-2601:26PM

Tracking Baker Brothers Portfolio: Q1 2026 UpdateSeekingAlpha

Jul-17-26

Jul-17-2604:21PM

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firmglobenewswire.com

Company

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	105	39	47	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	-2	0	0	—	—	—	—	—	—
Gross Profit	107	39	47	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	75	68	64	—	—	—	—	—	—
Research and Development	375	317	240	—	—	—	—	—	—
Other Operating Expense	8	4	5	—	—	—	—	—	—
Operating Income	-351	-349	-262	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	50	38	38	—	—	—	—	—	—
Net Income Before Taxes	-299	-312	-224	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-299	-311	-224	—	—	—	—	—	—
Net Income From Continuing Operations	-299	-312	-224	—	—	—	—	—	—
Net Income	-299	-311	-224	—	—	—	—	—	—
EPS (Recurring)	-3.25	-3.69	-2.98	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-3.25	-3.69	-2.98	—	—	—	—	—	—
EPS (Diluted)	-3.25	-3.69	-2.98	—	—	—	—	—	—
EBITDA	-292	-303	-216	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	101.34	167.59	64.20	—	—	—	—	—	—
Gross Margin	101.90	100.00	100.00	—	—	—	—	—	—
Operating Margin	-334.29	-894.87	-557.45	—	—	—	—	—	—
Net Margin	-284.76	-797.44	-476.60	—	—	—	—	—	—
Shares Outstanding	98	84	75	—	—	—	—	—	—
Market Capitalization	10,641	6,536	3,017	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mainolfi Nello	Chief Executive Officer	Jul 07 '26	Option Exercise	2.08	100,000	208,000	716,568	Jul 07
Mainolfi Nello	Chief Executive Officer	Jul 07 '26	Sale	119.00	50,000	5,950,000	666,568	Jul 07
Mainolfi Nello	Chief Executive Officer	Jul 01 '26	Sale	115.29	80,000	9,223,528	666,568	Jul 02
Goodman Noah	Chief Business Officer	Jul 01 '26	Sale	114.29	3,389	387,329	47,179	Jul 02
Mainolfi Nello	Chief Executive Officer	Jul 01 '26	Option Exercise	2.08	80,000	166,400	746,568	Jul 02
Jacobs Bruce N.	Chief Financial Officer	Jun 30 '26	Sale	114.96	77,109	8,864,829	244,883	Jul 02
Jacobs Bruce N.	Chief Financial Officer	Jun 30 '26	Option Exercise	5.33	61,378	327,145	321,992	Jul 02
Booth Bruce	Director	Jun 29 '26	Sale	108.05	153,300	16,563,805	461,794	Jul 02
Booth Bruce	Director	Jun 26 '26	Sale	110.29	467,878	51,603,032	472,267	Jun 30
BVF PARTNERS L P/IL	director, other: See Remarks and Footnotes	Jun 26 '26	Sale	106.50	1,630,658	173,665,078	78,787	Jun 26
Goodman Noah	Chief Business Officer	Jun 25 '26	Option Exercise	21.05	5,000	105,250	55,195	Jun 25
Booth Bruce	Director	Jun 25 '26	Sale	118.76	548,321	65,119,019	529,718	Jun 25
Goodman Noah	Chief Business Officer	Jun 25 '26	Sale	114.00	5,000	570,000	50,195	Jun 25
Booth Bruce	Director	Jun 24 '26	Sale	100.51	134,720	13,540,476	597,047	Jun 25
Booth Bruce	Director	Jun 23 '26	Sale	99.98	1,408	140,772	613,589	Jun 25

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.